Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

25.7%

9 terminated/withdrawn out of 35 trials

Success Rate

67.9%

-18.6% vs industry average

Late-Stage Pipeline

29%

10 trials in Phase 3/4

Results Transparency

16%

3 of 19 completed trials have results

Key Signals

1 recruiting3 with results7 terminated

Enrollment Performance

Analytics

Phase 3

9(52.9%)

Phase 2

7(41.2%)

Phase 4

1(5.9%)

17Total

Phase 3(9)

Phase 2(7)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials

NCT02099747Phase 3Completed

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

Role: lead

NCT01163942Phase 3Terminated

Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)

Role: lead

NCT04737785Completed

Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation

Role: lead

NCT05052385Completed

ECP Combination Study

Role: lead

NCT06267898Completed

Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

Role: lead

NCT02222272Completed

Effect of 2nd Gen TKI in CML

Role: lead

NCT01949129Phase 2Recruiting

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Role: collaborator

NCT00471848Phase 2Completed

Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia

Role: lead

NCT05063513Phase 2Withdrawn

Autologous Stem Cell Transplantation: International Lupus Trial

Role: lead

NCT05082675Phase 2Completed

Stem Cell Translpantation in Multiple Myeloma

Role: lead

NCT05077150Completed

A Case-control Study on Risk Factors, Timing, and PCR Use, for Pneumocystis Pneumonia (PcP) After Allogeneic HSCT

Role: lead

NCT00256776Phase 3Terminated

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Role: lead

NCT00766779Phase 3Terminated

HCT Versus CT in Elderly AML

Role: lead

NCT05049668Enrolling By Invitation

RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial

Role: lead

NCT01257854Unknown

Polymorphisms and Busulfan Pharmacokinetic Study

Role: collaborator

NCT03014986Completed

Current Treatment of HCV Infection After HSCT

Role: lead

NCT03014934Unknown

Impact of Pre-existing Invasive Aspergillosis on Allogeneic Stem Cell Transplantation

Role: lead

NCT00297193Phase 3Terminated

ASTIC Autologous Stem Cell Transplantation for Crohn's Disease

Role: lead

NCT04674280Unknown

Observational Study in Multiple Sclerosis Patients Treated With Autologous Hematopoietic Stem Cell Transplantation

Role: lead

NCT02059720Phase 3Unknown

Haplo-SCT vs ASCT With or Without Decitabine in AML CR1

Role: collaborator